Discovery of novel Henipavirus inhibitors
新型亨尼帕病毒抑制剂的发现
基本信息
- 批准号:10514154
- 负责人:
- 金额:$ 529.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-16 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAfrican Green MonkeyAnimalsAntiviral AgentsAntiviral TherapyAutomationBangladeshBiochemicalBiological AssayBiologyCase Fatality RatesCellsChemicalsCommunicable DiseasesContainmentCoronavirusCountryCrystallizationDengueDengue VirusDevelopmentDiseaseDisease OutbreaksDrug DesignDrug TargetingDrug resistanceEncephalitisEvaluationFamilyFlavivirusGenerationsGoalsHamstersHendra VirusHenipavirusHumanIn VitroIndiaInfectionLeadLuciferasesMalaysiaMapsMedicalMiniaturizationModelingModernizationMutationNipah VirusParamyxovirusPathogenicityPersonsPharmaceutical ChemistryPhase I/II Clinical TrialPhenotypePhilippinesProteinsRecombinantsResearchRodentServicesStructureStructure-Activity RelationshipSystemTechnologyTestingTexasTherapeuticTriageUniversitiesVaccinesVariantViralViral GenesVirusanimal efficacybasebiophysical techniquesbiosafety level 4 facilityclinical candidatecombatcytotoxicitydrug discoverydrug resistant virusefficacy studyhigh throughput screeninghuman pathogenin vivoin vivo Modelinhibitorlead optimizationmanmembernovelpandemic diseasepandemic preparednesspharmacokinetics and pharmacodynamicspre-clinicalpreclinical developmentprotective efficacyrespiratoryrespiratory pathogenreverse geneticssafety studyscreeningsmall moleculetooltransmission processvirologywhole genome
项目摘要
PROJECT 3 – ABSTRACT
The goal of this project is to discover novel henipavirus inhibitors. Henipavirus is a deadly airborne respiratory
pathogen that are under-researched and poorly understood. Antiviral therapy is urgently needed for
henipaviruses for pandemic preparedness. We will achieve the goal by pursuing three aims. (i) Screen and
identify novel compounds for Nipah and/or Hendra virus inhibition. Since Nipah and Hendra viruses should be
handled at BSL4, it is challenging to perform high-throughput screen at high containment. To overcome this
bottleneck, we will use a BSL2 Cedar henipavirus as a surrogate system for antiviral screen. Hits identified from
the Cedar henipavirus assay will be validated in Hendra and Nipah viruses at the BSL4 facility. (ii) Develop tool
compounds, determine target protein, and optimize molecules. (iii) Evaluate lead compounds in relevant in vitro
and in vivo models and select Development Candidate for IND-enabling studies. The proposed cell-based
approach may discover novel antiviral targets that may not be tractable for target-based antiviral approach.
项目3 -摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas William Geisbert其他文献
Thomas William Geisbert的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas William Geisbert', 18)}}的其他基金
Preclinical development of a vaccine for Nipah virus
尼帕病毒疫苗的临床前开发
- 批准号:
10214949 - 财政年份:2021
- 资助金额:
$ 529.18万 - 项目类别:
Preclinical development of a vaccine for Nipah virus
尼帕病毒疫苗的临床前开发
- 批准号:
10369731 - 财政年份:2021
- 资助金额:
$ 529.18万 - 项目类别:
Preclinical development of a vaccine for Nipah virus
尼帕病毒疫苗的临床前开发
- 批准号:
10576335 - 财政年份:2021
- 资助金额:
$ 529.18万 - 项目类别:
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine
克里米亚-刚果出血热病毒疫苗的临床前开发
- 批准号:
10217000 - 财政年份:2020
- 资助金额:
$ 529.18万 - 项目类别:
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine
克里米亚-刚果出血热病毒疫苗的临床前开发
- 批准号:
10655324 - 财政年份:2020
- 资助金额:
$ 529.18万 - 项目类别:
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine
克里米亚-刚果出血热病毒疫苗的临床前开发
- 批准号:
10440280 - 财政年份:2020
- 资助金额:
$ 529.18万 - 项目类别:
Core C - The University of Texas Medical Branch at Galveston
核心 C - 德克萨斯大学加尔维斯顿医学分校
- 批准号:
10362729 - 财政年份:2019
- 资助金额:
$ 529.18万 - 项目类别:
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
埃博拉和马尔堡病毒感染疫苗和治疗的进展
- 批准号:
9889877 - 财政年份:2019
- 资助金额:
$ 529.18万 - 项目类别:
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
埃博拉和马尔堡病毒感染疫苗和治疗的进展
- 批准号:
10356834 - 财政年份:2019
- 资助金额:
$ 529.18万 - 项目类别:
相似海外基金
AN AFRICAN GREEN MONKEY MODEL OF DENGUE HEMORRHAGIC FEVER
登革出血热非洲绿猴模型
- 批准号:
8358010 - 财政年份:2011
- 资助金额:
$ 529.18万 - 项目类别:
EVALUATION OF RECOMBINANT ATTENUATED RSV VACCINES IN THE AFRICAN GREEN MONKEY
非洲绿猴体内重组 RSV 减毒疫苗的评价
- 批准号:
6939778 - 财政年份:2003
- 资助金额:
$ 529.18万 - 项目类别:
PATHOBIOLOGY OF AFRICAN GREEN MONKEY RETROVIRUSES
非洲绿猴逆转录病毒的病理学
- 批准号:
3142662 - 财政年份:1989
- 资助金额:
$ 529.18万 - 项目类别:














{{item.name}}会员




